Thursday, October 01, 2015 9:01:15 AM
Caladrius Biosciences to Present at Multiple Upcoming October Conferences
October 1, 2015
Presentations to Highlight Company’s Cell Therapy Manufacturing and Therapeutic Development Programs
BASKING RIDGE, N.J. (October 1, 2015) – Caladrius Biosciences, Inc. (NASDAQ: CLBS), a cell therapy company combining an industry-leading external development and manufacturing provider with a development pipeline including a Phase 3 clinical program in immuno-oncology and a portfolio of projects in immune modulation and ischemic repair, announces today that the Company’s management will present at multiple conferences in October.
Stem Cell Meeting on the Mesa
•Website: stemcellmeetingonthemesa.com
•Venue: Estancia La Jolla Hotel, La Jolla, California
Session 1
•Date and Time: Wednesday, October 7, 2015, 7:15 AM PT
•Session Chair: Robert Preti, Senior Vice President, Development and Technical Operations and Chief Technology Officer, Caladrius; President of PCT
•Topic: Manufacturing & Scale-Up Workshop: Application of Traditional Drug & Biologics Development Principles to Regenerative Medicine
Session 2
•Date and Time: Wednesday, October 7, 2015, 11:00 AM PT
•Presenter: David Mazzo, Chief Executive Officer
•Topic: Company Presentation
Session 3
•Date and Time: Friday, October 9, 2015, 10:15 AM PT
•Poster Presenter: Candice Junge, Associate Vice President, Clinical Strategy and Commercial Assessment
•Topic: Evaluation of Safety & Efficacy of Autologous Ex Vivo Expanded TRegs (CLBS03) for the Treatment of New Onset Type 1 Diabetes Mellitus in an Adolescent Population
Session 4
•Date and Time: Friday, October 9, 2015, 10:15 AM PT
•Presenter: Gabriel Nistor, Vice President, Research
•Topic: Functional Properties of Patient-derived Melanoma Cancer Stem Cells Utilized as Treatment for Metastatic Melanoma in a Phase III Clinical Trial
Transcatheter Cardiovascular Therapeutics (TCT) 2015
•Website: http://www.crf.org/tct
•Venue: The Moscone Center, San Francisco, California
Session 1
•Date and Time: Thursday, October 15, 2015, 2:23 PM PT
•Lecturer: Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
•Topic: Cell-Based Therapies Prevent and Cure Heart Failure: More Than an Adventure
Session 2
•Date and Time: Thursday, October 15, 2015, 2:50 PM PT
•Discussant: Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
•Topic: Stem Cell Advances: Targeting Heart Failure
Session 3
•Date and Time: Thursday, October 15, 2015, 5:02 PM PT
•Discussant: Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
•Topic: Stem Cell Therapy Clinical Trials: Yes, We Can!
Cardiac Research Safety Consortium Sponsored Workshop for Cardiovascular Safety for Cell Therapies in Development for Cardiovascular Indications
•Date and Time: Friday, October 23, 2015, 10:35 AM ET
•Website: http://clbs.bio/csrcOct2015
•Venue: Sheraton College Park North Hotel, Beltsville, Maryland
•Presenter: Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
•Topic: Is Demonstration of Dose Dependency Required for Establishing Safety and Bioactivity
Cavendish Global Health Impact Forum
•Dates: Sunday, October 25 – Wednesday, October 28, 2015
•Website: http://cavendishglobal.com/2015-cleveland-clinic/
•Venue: Cleveland Clinic, Cleveland, Ohio
•Presenter: David Mazzo, Chief Executive Officer
•Topic: Company Presentation
2015 Till and McCulloch Meetings
•Date and Time: Tuesday, October 27, 2015, 11:25 AM ET
•Website: http://clbs.bio/tillmc15
•Venue: Sheraton Centre Hotel Toronto, Toronto, Ontario
•Presenter: Hans Keirstead, Senior Vice President, Research and Chief Science Officer
•Topic: Tumor-Initiating Cell-Based Immunotherapy for Cancer
Sofinnova Japan Biopharma Partnering Conference
•Date and Time: Tuesday, October 27, 2015, 9:05 AM JST
•Website: http://www.sofinnovajapanpartnering.com/
•Venue: Conrad Hotel, Tokyo, Japan
•Presenter: Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
•Topic: Company Presentation
About Caladrius Biosciences
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius combines a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. For more information, visit www.caladrius.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of cellular therapies with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s Immuno-Oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company’s wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.
Recent LSTA News
- Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial • GlobeNewswire Inc. • 09/17/2024 12:00:00 PM
- Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/12/2024 08:05:00 PM
- Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024 • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy • GlobeNewswire Inc. • 07/18/2024 12:00:00 PM
- Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma • GlobeNewswire Inc. • 07/16/2024 12:00:00 PM
- Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events • GlobeNewswire Inc. • 05/28/2024 12:30:00 PM
- Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer • GlobeNewswire Inc. • 05/20/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:16 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:13:47 PM
- Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 04/23/2024 11:30:00 AM
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Lisata Therapeutics to Present at BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM